Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL-18319 in Advanced Solid Tumors
NCT07903207Phase 1Not yet recruiting
- Sponsor
- Yingli Pharma
- Start
- Oct 2026
- Primary completion
- Nov 2028
01
Overview
Phase 1, open-label, single-arm trial of YL-18319 in solid tumor and ovarian cancer, sponsored by Yingli Pharma. Primary endpoint: Recommended Phase 2 Dose at 2 years. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
YL-18319
03
Conditions
solid tumorovarian cancer
Beyond the preview
Go deeper on NCT07903207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07903207.